NURO is committed to push the boundaries of technology for the well-being and betterment of human kind. We focus on complex problems and deliver powerful, innovative and safe solutions. We thrive in reaching further, deeper and in unprecedent ways.
Learn how NURO came to be and join us in this quest. That you are a client, a partner, an investor, let us build together solutions aiming to transform and enhance Life.
NURO was launched on the basis that better solutions in healthcare are critically
needed.
In today's world, science needs technology and both need business acumen to become
concrete deliverables. At NURO, we understand this need for a
multi-disciplinary approach to solving complex challenges and we have assembled some of
the top experts in the World in healthcare, science, advanced technologies and global
business to architect revolutionary products.
Our history has been marked by transformational events and numerous milestones on multiple continents. With your trust in us, we look forward to adding many more in the years to come.
ALZHEIMER'S + TRAUMA HIT HOME
NURO IS INCORPORATED
NURO GETS REGULATORY CLEARANCES
OUR FIRST PRODUCTS ARE LAUNCHED
With the help of the Canadian Government and the Kitchener-Waterloo tech ecosystem in
Ontario, NURO received its first acknowledgement and support in 2017.
From there, we are proud to say that we have been a cohort member of 5 of the top
Accelerators in the World, including in Silicon Valley, the Holy Grail of
Technology. In addition, our team has won multiple healthcare competitions
across North America, has been published by numerous leading publications in healthcare,
technology, science and business and has partnered with some of the most respected
hospitals and healthcare institutions.
Enjoy our journey and the important milestones we have reached so far...
Every single product at NURO is first based on Research. From
scientific publications to technological explorations to competitive analysis to
global market data to consultations with various leaders, our team spends a very
significant amount of time understanding in great depth our areas of interest to
ultimately ensure the very best delivery to our clients.
Because of the
nature of our work and our affiliations with governmental agencies, health
institutions and venture capitalists, we also have tremendous access to
specialized information and expert advice which guide us in our research and
allows us to create a multi-win strategy for all involved.
Our conceptualization work is defined by a vast array of decisions surrounding
the user first. We aim to understand what would work best, what would
be powerful yet still very easy-to-use for anyone. We take safety,
privacy, security, ergonomics and much more into constant
consideration. We look at how we can deliver optimal experiences
while at the same time understanding costs and regulations.
We start from
scratch and we then have literally hundreds of iterations and versionings in all
of our concepts and architectures. This extensive engineering work
has allowed us to fine-tune precisely what works very well and what allows
flexibility and growth in our product line.
All of the NURO products are in some ways inter-related from a development
perspective. This allows us to expand and accelerate our work and
also deliver relevant features based on a thoroughly-reinforced platform of
development.
Fundamentally, our products are what we define as multimodal and
multidirectional and they all encompass custom hardware, custom software,
algorithms and Artificial Intelligence, all working together to deliver the
power and the level of processing at which we need to operate.
Because we
also started in delivering solutions to humans in some of the most precarious
states of health, we target reliability, ease and speed of deployment.
Prior to releasing our first product architecture, NUOS, our team did six (6)
years of research, conceptualization, development and testing. We
first started internally and eventually received regulatory clearances for us to
proceed with third-party individuals under medical supervision, some of them, extremely advanced
pathophysiologically due to very advanced neurodegenerative diseases, stroke, trauma
and more.
One key patient-centric aspect of our firm is that we are able to continuously deliver new features based on the direct feedback we receive from our users. That is why
all of our products have unlimited free updates to make sure you get the very best from us at all times.
NURO is supported by some of the top Venture Capital firms, Angel Investors and
Governmental Agencies in the World.
Our work has been reviewed through extensive Due Diligence procedures and we have
gained the trust of these extraordinary individuals and their organizations by
devoting ourselves to hard work, facts and results.
We are grateful and honoured to list them here and we invite you to contact us if you have any question or are interested in joining us in this important journey.
SOSV | The Accelerator VC
SOSV is a global Venture Capital firm providing multi-stage investment
to develop and scale our founders’ big ideas for positive
change. SOSV invests in 150 companies every year through
their World-class vertical accelerator programs.
These intensive accelerators provide handpicked startups with
significant seed capital, a specialized global staff of engineers,
designers, researchers and scientists to accelerate product development,
mentors with deep market and technical expertise and an unparalleled
infrastructure of fully outfitted laboratory and operational spaces in
Silicon Valley and across the World.
NURO is proud to have been selected by and graduated from INDIE BIO, the World's
leading Life Science Accelerator, powered by SOSV out of San Francisco,
California.
Dr. David J. Kupfer, MD
Dr. David J. Kupfer, MD, Distinguished Professor Emeritus, Department of
Psychiatry, University of Pittsburgh School of Medicine, received his
bachelor's and MD degrees from Yale University. Dr. Kupfer
continued his postgraduate clinical and research training at the Yale
New Haven Hospital and the National Institute of Mental Health
(NIMH). With a dual board certifications in Psychiatry and in
Neurology, Dr. Kupfer became the Chair of the Department of Psychiatry
at the University of Pittsburgh School of Medicine and the Director of
Research at Western Psychiatric Institute and Clinic. Under
Dr. Kupfer's direction, WPIC became one of the United States' preeminent
university-based psychiatric research centers.
A prolific writer, Dr. Kupfer has authored and co-authored a combination
of more than 1,000 articles, books, and book chapters. He is
internationally recognized for his role as Chair of the DSM-5, the Task
Force behind the Diagnostic and Statistical Manual of Mental Disorders,
a product of more than 10 years of research by hundreds of international
experts in all aspects of mental health. In recognition of
his contributions, Dr. Kupfer has been the recipient of a very large
collection of awards and honors including his 1990 election to the
National Academy of Medicine.
We are honoured and absolutely thrilled to have Dr. Kupfer in our team as both an investor and an esteemed member of our Board of Directors.
Dr. Laghrissi-Thode, MD, PhD
Dr. Laghrissi-Thode, MD, PhD, has held positions of leadership at
AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic
areas, including central nervous system, cardiovascular, metabolic
disease and genito-urinary health.
She is currently the Chief Executive Officer and a member of the Board
of Directors of DalCor Pharmaceuticals. Prior to joining
DalCor, Dr. Laghrissi-Thode was Vice-President (Therapy) at AstraZeneca
and also the Head of their South San Francisco site and the Chief
Executive Officer of ZS Pharma, Inc.
In her previous roles she led the global product and portfolio strategy
of the cardiovascular, metabolism and renal therapeutic areas at
AstraZeneca and Roche. She has more than 20 years of pharmaceutical
industry leadership experience in US and Europe through working in
clinical development, global strategic marketing, business development,
licensing and Mergers & Acquisitions. She served as a board
member of the Healthcare Businesswomen’s Association (HBA) Europe and
was recognized by HBA in 2012 for her work in developing and promoting
women leadership in healthcare. Dr. Laghrissi-Thode holds her
Medical Doctorate from the University of Tours School of Medicine in
France.
We are honoured and absolutely thrilled to have Dr. Laghrissi-Thode in our team as both an investor and an esteemed member of our Board of Directors.
The Province of Ontario, Canada | The Ontario Centres of
Excellence
NURO is honoured to be the recipient of an investment from the Province
of Ontario, Canada via the Ontario Centres of Excellence.
On behalf of the Province of Ontario and the Government of Ontario, the
Ontario Centres of Excellence supports early-stage companies that are
raising pre-seed and seed investments via a competitive investment
fund. With more than 300 companies considered for funding
each year, OCE only selects and completes 20 investments a year.
Companies are reviewed through a rigorous internal pre-vetting process
before being selected to proceed to an investment advisory committee for
consideration. Companies are evaluated based on their
potential long-term competitiveness, strong IP, unique value proposition
and momentum/capacity to scale with a preference given to companies that
exhibit a substantially unique offering that differentiates them in the
marketplace.
NURO would have never been able to achieve its milestones and our current trajectory
without the assistance and the trust that the following organizations have generously
given us.
Our team is humbled by your recognition and support and we thank you
for having allowed us to count on you throughout these years of dedication and focus on
missions that seemed almost impossible to reach. Our success is just as much
ours as it is yours.
NURO was streamed live on TechCrunch from San Francisco for INDIE BIO's Demo Day 2018.
After almost 5 months in Silicon Valley, 14 companies graduated from what is considered the leading Life Science Accelerator in the World and also one of the toughest programs for entrepreneurs on the planet. NURO, not only graduated with only its Founder and CEO on-location for the entire duration of the program, but also managed to grab the last famous "Killer of the Week" Award with an incredible milestone achieved in Palo Alto with a brain stem stroke patient using NUOS live successfully for the very first time.
READ MORE
Fast Company has always been a publication that any entrepreneur would love to be mentioned into... We were honoured by this article under their WORLD CHANGING IDEAS category.
For the first time, NUOS, the Neural Operating System got into the public spotlight. After hundreds of iterations, we had finally reached a viable architecture, a technical foundation, a platform which would allow our team to not only deliver a solution to highly incapacitated patients, their families, their doctors and caregivers but also allow us to keep on developing on our multimodal signal processing and ultimately deliver a first in its class when it comes to reliable assistive communication and non-invasive brain-to-computer interfacing.
READ MORE
The title of that article says it all...
An in-depth coverage was done by the highly-respected tech journalist, Erin Brodwin, on what NURO had accomplished in 2018 during our Silicon Valley residency. This was an important new validation for our team and a confirmation that our work was starting to be valuable to patients in need and certainly noticeable to the rest of the World and other significant efforts in the field of neurotechnology.
READ MORE
It is not everyday we are listed next to a billion dollar acquisition in our industry...
This article primarily talks about CTRL-Labs which was a firm specializing in neurotechnology or what we actually determine to be an enhanced electromyography system (remember the MYO from our friends at Thalmic Labs in Waterloo ?) Anyway, that team did amazing processing muscular signals from your wrist (yup, that was not the brain) and got bought out by Facebook for what was reported to be a fresh one billion dollars !... Not a bad day at the office :)
Now the cooler thing is that NURO has a paragraph in that article too... Thank you Nanalyze !
Read MORE
For those who do not know, The Royal Society is a Fellowship of many of the World's most eminent scientists and is the oldest scientific academy in existence.
In this important publication, The Royal Society takes a deeper look into neural and brain-computer interfaces. We are honoured to be a part of the iHuman Report and certainly look forward to continuing our interaction with this exceptional organization.
READ MORE
Thank you to Forbes for including NURO in this excellent publication on Neurotechnology and Artificial Intelligence.
Did you know that over $19 billion has been invested in Neurotech companies in the last 20 years ? This and much more can be found in this reference article about our industry. One can see an overview of the global NeuroTech landscape in 2020 with over 200 companies worldwide working on different areas such as NeuroModulation, NeuroImaging, NeuroPharmacology and of course Brain Computer Interfaces in which NURO fits with 12 other firms. Always thrilled to be a part of this massive effort and most grateful for a name like Forbes to include us in their work and output to the World.
READ MORE
Our team is absolutely thrilled to announce it has officially been selected by Google Canada for its inaugural Google Cloud Accelerator.
Google is one of the most advanced Cloud platforms in the World and its technologies for Artificial Intelligence, Machine Learning and Deep Learning are in a class of their own. Further, Google's interests in Healthcare and incredible tools to assist human kind are in harmony with both our own technological developments and our core philosophy. We are proud to be selected with 11 other firms for this incredible accelerator and very much look forward to establishing a strong and fruitful collaboration with Google, the Google Developers and Industry Mentors.
READ MORE
